Clinical studies implementing glutamate neurotransmission in mood disorders.
about
The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulationNeurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodentsStress as a one-armed bandit: Differential effects of stress paradigms on the morphology, neurochemistry and behavior in the rodent amygdala.New approaches to antidepressant drug discovery: beyond monoaminesDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsA genome-wide association study of antidepressant response in KoreansBipolar disorder: candidate drug targets.An update of the classical and novel methods used for measuring fast neurotransmitters during normal and brain altered functionAdvances in the treatment of anxiety: targeting glutamate.Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.Prefrontal cortex glutamate correlates with mental perspective-taking.Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addictionEnhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action.Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzoleNovel drugs and therapeutic targets for severe mood disorders.Disturbance of the glutamatergic system in mood disorders.Hippocampal interneurons in bipolar disorder.Estrogen receptor beta expression in the embryonic brain regulates development of calretinin-immunoreactive GABAergic interneurons.Proton magnetic resonance spectroscopy in depressionMania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex.GABA and glutamate systems as therapeutic targets in depression and mood disorders.Glutamate modulators as novel interventions for mood disorders.The same antidepressant elicits contrasting patterns of synaptic changes in the amygdala vs hippocampusCandidate genes for antidepressant response to selective serotonin reuptake inhibitorsGlutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male miceGliogenesis and glial pathology in depression.From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disordersAbnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.Early intervention in bipolar disorder, part II: therapeuticsContribution of methotrexate in precipitation of manic episode in bipolar affective disorder explored: a case reportGlial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors.Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonistPreliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression.Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategyImproving antidepressant drugs: update on recently patented compounds.Glutamate and choline levels predict individual differences in reading ability in emergent readers.Investigational NMDA receptor modulators for depression.
P2860
Q24613593-293929E7-21F4-49B5-8C92-A03E80354AB8Q24656267-F3540E06-5E65-40C0-B276-0C94C16DE588Q26769043-D37E586C-F276-48C7-B508-257D14A5E0FEQ28293089-178EE143-4383-49C3-84C2-317B70DCDA6AQ28305100-CABD1980-C1DC-4D04-AC22-83B58D2A67B6Q28597255-F0F87920-35D8-47AE-8C8F-EC7F386C8647Q28751133-4F75C866-23F9-4FF2-91D6-4763020D84A4Q30410156-66000BC5-E275-461B-96E4-BF682C93EB1BQ30457479-D58CAC34-974D-4252-9C03-386B14686220Q31032734-54380BAA-94CB-4028-ABEA-C89BDBF05F7CQ33389974-95BBE792-6658-4060-A8E0-D6F90D5FE669Q33390364-EB553293-6F25-417E-B7E4-9E658019892CQ33553152-C3065E56-5573-4819-86CA-6EC6DE7331BFQ34359105-D1EA0405-5CEE-4197-927D-DA51188D9FC0Q34522617-1B0A37AD-8181-4677-9BD0-57252CA0F075Q34661581-19FBC758-1C28-4A27-84F0-2C4272BE062BQ34732759-734719B8-238E-4326-8700-7A1927245CFCQ35149888-4B231C57-240C-4F89-9F98-0B563D19DE53Q35400508-72A8D51B-0497-46DB-BE1F-61F36DC1FED9Q35539953-23FCF7DC-B8A1-4706-922C-6C8DAB8844B8Q35702054-2222C21F-7EF9-4F57-8BCE-AF0249D8C21EQ35747079-8A091193-3970-4037-81FA-24D1BAB9CA4FQ36066308-090E997C-B122-4547-AD1E-345489033403Q36285982-F493BB33-40A9-4D46-AECB-0682CA4D8FA9Q36323561-DDA17334-F286-4D84-A481-97419B392424Q36718053-B3030626-7BA5-4AB1-9467-BB98DB06A4EEQ36788384-CCB67FA0-5688-4B7D-8C49-36BDB7882135Q36825936-908FF97D-718F-4957-83E8-AA1A11E18179Q36944201-5CE29110-E4AC-4CCF-9BAD-94A035E6CC39Q36960864-BC63CF82-CB7B-4538-AF2D-1D25D8342968Q37071007-3BDAFDC0-1111-4A45-8F73-27B1561C96A6Q37248070-B32855DD-5D85-46FA-8898-CABB7477FCCBQ37259435-6443FEC4-73BC-43EB-B497-AD57305997CFQ37307000-4F8210D9-ADDA-4DE6-868B-AF381E504ECAQ37368290-2F422971-7E5A-4226-BC32-5ACE7E7EE4E4Q37408446-100FBBDE-2CC5-49CB-8899-9B9E18B37297Q37456927-30BE59C7-1C72-4428-B021-D79242368553Q37497379-A245AEDB-3493-4A6A-BD32-739F0E1FE3E6Q37633638-861244E1-D388-44B8-9D72-2C4550CC450BQ37957965-511295CD-F071-4FF3-BC3A-58EE7E580D65
P2860
Clinical studies implementing glutamate neurotransmission in mood disorders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical studies implementing glutamate neurotransmission in mood disorders.
@ast
Clinical studies implementing glutamate neurotransmission in mood disorders.
@en
type
label
Clinical studies implementing glutamate neurotransmission in mood disorders.
@ast
Clinical studies implementing glutamate neurotransmission in mood disorders.
@en
prefLabel
Clinical studies implementing glutamate neurotransmission in mood disorders.
@ast
Clinical studies implementing glutamate neurotransmission in mood disorders.
@en
P2093
P2860
P356
P1476
Clinical studies implementing glutamate neurotransmission in mood disorders.
@en
P2093
Douglas L Rothman
Gerard Sanacora
Graeme Mason
John H Krystal
P2860
P304
P356
10.1196/ANNALS.1300.018
P407
P577
2003-11-01T00:00:00Z